A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma

Owen A. O'Connor, Carol Portlock, Craig Moskowitz, David Straus, Paul Hamlin, Michael Stubblefield, Otila Dumetrescu, A. Dimitrios Colevas, Barbara Grant, Andrew Zelenetz

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

The epothilones represent a novel group of microtubule stabilization agents that appear to retain activity even in chemotherapy-resistant cell lines and animal models. Because of their ability to overcome chemotherapy resistance, we conducted a phase II study of Ixabepilone in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma (MCL). Ixabepilone was given at a dose of 25 mg/m2 weekly for three of four consecutive weeks. Patients were required to have received ≤4 prior chemotherapy regimens, with an interval of at least one month since the last treatment, 3 months from prior rituximab, and 7 d from prior steroids, an absolute neutrophil count >1 × 10 9/l and a platelet count >50 × 109/l. Dose reductions were allowed. The overall response rate in assessable patients was 27% in this otherwise heavily treated population. One patient with chemotherapy-refractory follicular lymphoma attained a complete remission that lasted approximately 8 months. Three responses were also seen in refractory MCL and one in small lymphocytic lymphoma. The duration of response ranged from 2 to 8 months. Major toxicities included fatigue, myelosuppression and neuropathy. These data suggest that Ixabepilone has activity in chemotherapy-refractory lymphoma.

Original languageEnglish (US)
Pages (from-to)201-209
Number of pages9
JournalBritish Journal of Haematology
Volume143
Issue number2
DOIs
StatePublished - Oct 1 2008
Externally publishedYes

Fingerprint

Epothilones
Mantle-Cell Lymphoma
Non-Hodgkin's Lymphoma
Drug Therapy
Follicular Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Platelet Count
Microtubules
Fatigue
Lymphoma
Neutrophils
Animal Models
Steroids
ixabepilone
Cell Line
Population

Keywords

  • Epothilones
  • Indolent non-Hodgkin lymphoma
  • Ixabepilone
  • Mantle cell lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma. / O'Connor, Owen A.; Portlock, Carol; Moskowitz, Craig; Straus, David; Hamlin, Paul; Stubblefield, Michael; Dumetrescu, Otila; Colevas, A. Dimitrios; Grant, Barbara; Zelenetz, Andrew.

In: British Journal of Haematology, Vol. 143, No. 2, 01.10.2008, p. 201-209.

Research output: Contribution to journalArticle

O'Connor, Owen A. ; Portlock, Carol ; Moskowitz, Craig ; Straus, David ; Hamlin, Paul ; Stubblefield, Michael ; Dumetrescu, Otila ; Colevas, A. Dimitrios ; Grant, Barbara ; Zelenetz, Andrew. / A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma. In: British Journal of Haematology. 2008 ; Vol. 143, No. 2. pp. 201-209.
@article{24e0e2409bbe47f9aaee2edc2b6ce2d2,
title = "A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma",
abstract = "The epothilones represent a novel group of microtubule stabilization agents that appear to retain activity even in chemotherapy-resistant cell lines and animal models. Because of their ability to overcome chemotherapy resistance, we conducted a phase II study of Ixabepilone in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma (MCL). Ixabepilone was given at a dose of 25 mg/m2 weekly for three of four consecutive weeks. Patients were required to have received ≤4 prior chemotherapy regimens, with an interval of at least one month since the last treatment, 3 months from prior rituximab, and 7 d from prior steroids, an absolute neutrophil count >1 × 10 9/l and a platelet count >50 × 109/l. Dose reductions were allowed. The overall response rate in assessable patients was 27{\%} in this otherwise heavily treated population. One patient with chemotherapy-refractory follicular lymphoma attained a complete remission that lasted approximately 8 months. Three responses were also seen in refractory MCL and one in small lymphocytic lymphoma. The duration of response ranged from 2 to 8 months. Major toxicities included fatigue, myelosuppression and neuropathy. These data suggest that Ixabepilone has activity in chemotherapy-refractory lymphoma.",
keywords = "Epothilones, Indolent non-Hodgkin lymphoma, Ixabepilone, Mantle cell lymphoma",
author = "O'Connor, {Owen A.} and Carol Portlock and Craig Moskowitz and David Straus and Paul Hamlin and Michael Stubblefield and Otila Dumetrescu and Colevas, {A. Dimitrios} and Barbara Grant and Andrew Zelenetz",
year = "2008",
month = "10",
day = "1",
doi = "10.1111/j.1365-2141.2008.07271.x",
language = "English (US)",
volume = "143",
pages = "201--209",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - A multicentre phase II clinical experience with the novel aza-epothilone Ixabepilone (BMS247550) in patients with relapsed or refractory indolent non-Hodgkin lymphoma and mantle cell lymphoma

AU - O'Connor, Owen A.

AU - Portlock, Carol

AU - Moskowitz, Craig

AU - Straus, David

AU - Hamlin, Paul

AU - Stubblefield, Michael

AU - Dumetrescu, Otila

AU - Colevas, A. Dimitrios

AU - Grant, Barbara

AU - Zelenetz, Andrew

PY - 2008/10/1

Y1 - 2008/10/1

N2 - The epothilones represent a novel group of microtubule stabilization agents that appear to retain activity even in chemotherapy-resistant cell lines and animal models. Because of their ability to overcome chemotherapy resistance, we conducted a phase II study of Ixabepilone in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma (MCL). Ixabepilone was given at a dose of 25 mg/m2 weekly for three of four consecutive weeks. Patients were required to have received ≤4 prior chemotherapy regimens, with an interval of at least one month since the last treatment, 3 months from prior rituximab, and 7 d from prior steroids, an absolute neutrophil count >1 × 10 9/l and a platelet count >50 × 109/l. Dose reductions were allowed. The overall response rate in assessable patients was 27% in this otherwise heavily treated population. One patient with chemotherapy-refractory follicular lymphoma attained a complete remission that lasted approximately 8 months. Three responses were also seen in refractory MCL and one in small lymphocytic lymphoma. The duration of response ranged from 2 to 8 months. Major toxicities included fatigue, myelosuppression and neuropathy. These data suggest that Ixabepilone has activity in chemotherapy-refractory lymphoma.

AB - The epothilones represent a novel group of microtubule stabilization agents that appear to retain activity even in chemotherapy-resistant cell lines and animal models. Because of their ability to overcome chemotherapy resistance, we conducted a phase II study of Ixabepilone in patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma (MCL). Ixabepilone was given at a dose of 25 mg/m2 weekly for three of four consecutive weeks. Patients were required to have received ≤4 prior chemotherapy regimens, with an interval of at least one month since the last treatment, 3 months from prior rituximab, and 7 d from prior steroids, an absolute neutrophil count >1 × 10 9/l and a platelet count >50 × 109/l. Dose reductions were allowed. The overall response rate in assessable patients was 27% in this otherwise heavily treated population. One patient with chemotherapy-refractory follicular lymphoma attained a complete remission that lasted approximately 8 months. Three responses were also seen in refractory MCL and one in small lymphocytic lymphoma. The duration of response ranged from 2 to 8 months. Major toxicities included fatigue, myelosuppression and neuropathy. These data suggest that Ixabepilone has activity in chemotherapy-refractory lymphoma.

KW - Epothilones

KW - Indolent non-Hodgkin lymphoma

KW - Ixabepilone

KW - Mantle cell lymphoma

UR - http://www.scopus.com/inward/record.url?scp=52649085233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52649085233&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2008.07271.x

DO - 10.1111/j.1365-2141.2008.07271.x

M3 - Article

VL - 143

SP - 201

EP - 209

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -